Skip to main
STAA

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 25%
Buy 13%
Hold 50%
Sell 0%
Strong Sell 13%

Bulls say

Staar Surgical is poised for long-term success, with a strong leadership team in place and a solid portfolio of phakic intraocular lenses that are in high demand, specifically in China. This is evident from their current financial results, with a significant increase in revenue and a positive outlook for future growth in the country. Their competitive moat, reinforced by their proprietary Collamer material and established track record, is further enhanced by their focus on surgeon training and clinic workflows. With a potential market share ramp for competitors such as EyeBright, monitoring their progress will be important, but we believe that Staar Surgical's strong brand equity and technological lead will allow them to maintain their dominant market position.

Bears say

Staar Surgical is heavily reliant on its ICL products, which may hinder long-term growth as the market for intraocular procedures is largely dominated by laser-based alternatives. Moreover, the company's narrow focus on the refractive surgery market leaves it vulnerable to competition and shifts in consumer preference. Lastly, strong support for ICL adoption among younger and newer surgeons is not a guarantee for sustained sales growth as these surgeons may choose to prioritize other procedures or shift to alternative techniques in the future.

STAAR Surgical (STAA) has been analyzed by 8 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 13% recommend Buy, 50% suggest Holding, 0% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Hold based on their latest research and market trends.

According to 8 analysts, STAAR Surgical (STAA) has a Hold consensus rating as of Sep 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.